Multiparametric cardiac magnetic resonance identifies macrophage nitric oxide synthase 2-mediated benefits of preventive sodium-glucose cotransporter 2 inhibition in a mouse model of metabolic heart disease
In this obesity-related metabolic heart disease model, EMPA treatment prevents cardiometabolic dysfunction by improving EAT quantity and quality, coronary microvascular function, and diastolic function. These benefits are mediated in part through macrophage NOS2.
Authors
- André Marette (ORCID: https://orcid.org/0000-0003-3950-5973)
- Leigh Bradley
- Brant E. Isakson (ORCID: https://orcid.org/0000-0002-7692-6294)
- Christopher M. Kramer (ORCID: https://orcid.org/0000-0003-2057-7731)
- Brent A. French (ORCID: https://orcid.org/0000-0002-9933-3854)
- Amit R. Patel (ORCID: https://orcid.org/0000-0001-7621-6463)
- Julia Bresticker
- Edgar Macal
- Frederick H. Epstein (ORCID: https://orcid.org/0000-0002-1954-1988)
- Matthew J. Wolf (ORCID: https://orcid.org/0000-0001-8004-4852)
- Caitlin Pavelec
- John T. Echols (ORCID: https://orcid.org/0000-0001-7485-4912)
- Rahul Roy
- Thomas P. Skacel
Institutions
- Lung Institute (US)
- University of Virginia (US)
Publication Details
- Journal
- Journal of Cardiovascular Magnetic Resonance
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.jocmr.2025.101972
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29